Alon Ben-Noon Buys Shares of NRSN $NRSN
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Alon Ben-Noon, Chief Executive Officer at NeuroSense Therapeutics Ltd. ($NRSN), bought 250,000 shares at an average price of $0.80, for a total transaction of $200,000. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
NeuroSense Therapeutics Ltd. Stock Up 67.7%
Shares of NeuroSense Therapeutics Ltd. ($NRSN) traded around $0.70 on Wednesday, up 67.7% for the day.
NeuroSense Therapeutics Ltd. Earnings
Analysts Set New Price Targets
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Get NeuroSense Therapeutics Ltd. alerts
New 13F filings, insider trades, and analyst moves on $NRSN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.